Monday, May 16, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Licensing Opportunity: Virus-Like Particle Technology for Universal Flu Vaccine

by Global Biodefense Staff
July 13, 2021
Licensing Opportunity: Virus-Like Particle Technology for Universal Flu Vaccine

Colorized structure of prototype universal flu vaccine nanoparticle. Foreground image: NIAID, modified.

Reformulating influenza vaccines annually against dominant circulating strains leads to variable protective efficacy and is unlikely to protect against novel influenza viruses with pandemic potential. Thus, there is a great need for a vaccine that provides “universal” protection against influenza viruses.

The National Institutes of Health (NIH) has a Technology Transfer opportunity available for a virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes.

The technology has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes, further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine.

Read more about this tech transfer opportunity or contact Elizabeth Pitts, Ph.D. at 240-669-5299 or elizabeth.pitts@nih.gov.

Source: National Institutes of Health, adapted.

RELATED:

  • A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice Immunological Investigations
  • Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus Vaccine
  • Intranasal Vaccination with 1918 Influenza Virus-Like Particles Protects Mice and Ferrets from Lethal 1918 and H5N1 Influenza Virus Challenge ASM
  • Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice Virology
Tags: Editor PickInfluenzaInnovationNIAIDTech Transfer

Related Posts

NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity
Biosecurity

U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity

April 13, 2022
Yersinia pestis
Funding News

NIH Awards $3M Grant to Albany Med for Plague Vaccine Development

April 8, 2022
State Department: Reducing Revisionist State Biological and Chemical Weapons Threats
CBRNE

CounterACT: U.S. Funding Early Stage Drug Discovery of Countermeasures Against Chemical Threats

March 21, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC